This study, called PLUMM, is looking at two different ways to give a medicine called Mycophenolate Mofetil (MMF) to children and young adults (ages 8 to 20) with lupus nephritis. Lupus nephritis is a kidney condition caused by lupus. One way of giving MMF is based on body size, and the other is a more personalized approach based on how your body processes the medicine. The study wants to see which method is more effective at treating lupus nephritis after 26 weeks. To join, you must have lupus and a recent diagnosis of proliferative lupus nephritis confirmed by a kidney biopsy. The study is currently recruiting participants.

Study design

This is a double-blinded study with two groups, meaning neither you nor your doctor will know which MMF dosing method you are receiving. It plans to enroll 105 participants.

What's involved

You would receive blinded treatment for up to 53 weeks. You would also have study visits at weeks 26 and 53/End of Study.

Compensation

Not stated in the trial record.

Follow-up

The primary goal is measured at 26 weeks, and the study continues for up to 53 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.